<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181972</url>
  </required_header>
  <id_info>
    <org_study_id>1118.2</org_study_id>
    <nct_id>NCT02181972</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults</brief_title>
  <official_title>Efficacy and Safety of Gingko Biloba Film-coated Tablets (2 x 60 mg Daily p.o.) in Improving Cognitive Functions and Neuropsychological Functioning of Middle-aged Cognitively Intact Adults: a Double-blind, Placebo-controlled, Parallel Group, Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study was to assess the efficacy and safety of Gingko biloba
      film-coated tablets in improving cognitive function and neuropsychological functioning of
      middle-aged cognitively intact adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of the cognitive test/CDR (Cognitive Drug Research) factor &quot;Power of Attention)</measure>
    <time_frame>pre-dose and 2, 4, 6 hours post-dosing at baseline and day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CDR factors</measure>
    <time_frame>pre-dose and 2, 4, 6 hours post-dosing at baseline, days 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Stroop Colour and Word Test</measure>
    <time_frame>Baseline and day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the Selective Reminding Test</measure>
    <time_frame>Baseline and day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the Trail Making Test (Part A and B)</measure>
    <time_frame>Baseline and day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>Baseline, days 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>Baseline and day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by subject on a 4-point scale</measure>
    <time_frame>Days 28 and 58</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>Days 28 and 58</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Gingko biloba</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gingko biloba</intervention_name>
    <arm_group_label>Gingko biloba</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female healthy subjects with no known clinically significant pathology as
             assessed by the investigator

          -  Mini-Mental State Examination (MMSE) score â‰¥ 28

          -  Age range: 40 to 60, inclusive

          -  Females must test negative for pregnancy

          -  Clinical laboratory tests must be within normal limits or, if out of normal range,
             clinically acceptable to the Investigator

          -  Urine drug screen for illicit drugs must be negative at screening

          -  Subjects must have given written informed consent in accordance with ICH-GCP
             (International Conference on Harmonization - Good Clinical Practice) and local laws
             and regulations

        Exclusion Criteria:

          -  Any serious disorder that may interfere with his/her participation in the trial and
             the evaluation of the safety of the test drug

          -  Pre-treatment and/or concomitant treatment with any drug that may influence the trial
             symptomatology and may interfere with the evaluation of cognitive function

          -  Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistics Manual, Version
             IV)

          -  Individuals drinking more than 6 cups of coffee or tea/day

          -  Individuals smoking more than 10 cigarettes/day

          -  Subjects who in the opinion of the investigator are heavy users of other tobacco or
             nicotine products

          -  Subjects currently taking a cognition enhancing substance, including any Ginkgo or
             ginseng product

          -  Any subject regularly taking a medication who might stop doing so at some time during
             the active dosing phase, if the medication is deemed by the investigator to influence
             the outcome of the trial

          -  Female subjects of child-bearing age who are not using adequate means of birth control

          -  Pregnancy and/or lactation

          -  Any subject who, according to the Investigator, is unable to perform the CDR cognitive
             tests or the neuropsychological tests in a satisfactory and consistent manner

          -  Relevant allergy or known hypersensitivity to the investigational product or its
             excipients

          -  Individuals under anticoagulant treatment

          -  Individuals with a current disorder likely to modify computerised cognitive testing

          -  Individuals having a history of cancer (any type, excluding surgically removed and
             treated basal cell carcinoma)

          -  Clinically significant and not treated thyroid disease

          -  Participation in another clinical trial within the last 3 months prior to the start of
             the study and concurrent participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

